Drug intelligence / Profile preview

MEBO Dermhealth Cream

Development stage: Unknown
Lead developer: Shantou MEBO Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

**MEBO Dermhealth Cream** is a topical fixed-dose dermatologic combination developed and manufactured by Shantou MEBO. It contains miconazole nitrate, neomycin sulfate, and triamcinolone acetonide acetate in a sesame-oil cream base. Miconazole provides antifungal activity, neomycin provides antibacterial activity, and triamcinolone acetonide acetate is a corticosteroid intended to reduce inflammation and allergic skin symptoms. The product is marketed for eczema, contact dermatitis, seborrheic dermatitis, neurodermatitis, and dermatophyte infections including tinea pedis, tinea cruris, tinea corporis, and tinea manuum.

Brand names: MEBO DermhealthMEBO Dermhealth Cream

Targets

Bacterial RibosomeCYP51A1 (Sterol 14α-demethylase)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on MEBO Dermhealth Cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEBO Dermhealth Cream.

Explore the full profile